A precision medicine approach to Alzheimer’s disease

By integrating information from a well-understood drug agent, a large dataset in patients with the active molecule tramiprosate, novel genetic markers and insights into the pathology of Alzheimer’s disease (AD), we have created ALZ-801, an optimized prodrug of tramiprosate.  ALZ-801 is one of the few drug candidates in advanced stages of clinical testing in AD, a pill with a favorable safety profile and the potential to modify an underlying cause of the disease.

About ALZ-801

In the news